Exhortations to abandon the Pap test as a routine initial cervical screening test are still premature and carry significant risks

Diagnostic Cytopathology

Volumn 38, Issue 11, 2010, Pages 783-787

  Austin, R Marshall ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER SCREENING; COST BENEFIT ANALYSIS; CYTOPATHOLOGY; EDITORIAL; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 78349293416     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21350     Document Type: Editorial

References (74)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12 -19.
2. zur Hausen H,. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002; 2: 342 -350.
3. Castle PE,. The evolving definition of carcinogenic Human Papillomavirus. Infect Agent Cancer 2009; 4: 7.
4. Solomon D, Breen N, McNeel T,. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 2007; 57: 105 -111.
5. Lörincz AT, Richart RM,. Human Papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127: 959 -968.
6. International Agency for Research on Cancer. IARC/WHO handbooks of cancer prevention: Cervix cancer screening. Vol. 10. Lyon: IARC Press; 2005. p 1 -302.
7. Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM,. EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer 2009; 125: 2246 -2255.
8. Anttila A, Ronco G,; Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009; 45: 2685 -2708.
9. Wright TC,. Cervical cancer screening in the 21st century: Is it time to retire the Pap smear? Clin Obstet Gynecol 2007; 50: 313 -323.
10. Schiffman M, Wacholder S,. From India to the world-A better way to prevent cervical cancer. N Engl J Med 2009; 360: 1453 -1455.
11. Cox T, Cuzick J,. HPV DNA testing in cervical cancer screening: From evidence to policies. Gynecol Oncol 2006; 103: 8 -11.
12. Stoler M,. HPV vaccine to transform testing protocol. Profession sooner rather than later. Crit Care 2009; 2: 26 -27.
13. Castle PE,. Invited commentary: Is monitoring of Human Papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol 2008; 168: 138 -144; discussion 145-148.
14. Schiffman M, Solomon D,. Screening and prevention methods for cervical cancer. JAMA 2009; 302: 1809 -1810.
15. Disclosure of Financial Support. Prevention of Cervical Cancer: Progress and Challenges on HPV Vaccination and Screening. Vaccine 2008; 26 (Suppl 10): K93.
16. Cuzick J, Clavel C, Petry KU, et al. Overview of North American Studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095 -1101.
17. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E,. Diagnostic accuracy of Human Papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104: 232 -246.
18. Sankaranarayanan R, Chatterji R, Shastri SS, Wesley RS, Basu P, Mahe C, Muwonge R, Seigneurin D, Somanathan T, Roy C, Kelkar R, Chinoy R, Dinshaw K, Mandal R, Amin G, Goswami S, Pal S, Patil S, Dhakad N, Frappart L, Fontaniere B,. Accuracy of Human Papillomavirus testing in primary screening of cervical neoplasia: Results from a multicenter study in India. Int J Cancer 2004; 112: 341 -347.
19. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P,. Screening with a primary Human Papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008; 44: 565 -571.
20. Massad LS,. Beyond sensitivity. J Lower Gen Tract Dis 2008; 12: 311 -315.
21. Sherman ME, Dasgupta A, Schiffman M, Nayar R, Solomon D,. The Bethesda Interobserver Reproducibility Study (BIRST): A web-based assessment of the Bethesda 2001 System for classifying cervical cytology. Cancer Cytopathology 2007; 111: 15 -25.
22. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J,. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88 -99.
23. Cuzick J, Szarewski A, Cuble H, Kitchener H, Luesley D, McGoogan E, Menon, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, jacobs I, Pickles C, Sasieni P,. Management of women who test positive for high-risk types of Human Papillomavirus: The HART study. Lancet 2003; 362: 1871 -1876.
24. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL,; Canadian Cervical Cancer Screening Trial Study Group. Human Papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579 -1588.
25. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ,. Cost-effectiveness of cervical cancer screening with Human Papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100: 308 -320.
26. Castle P, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W,. Five-year experience of Human Papillomavirus DNA and Papanicolaou test co-testing. Obstet Gynecol 2009; 113: 595 -600.
27. Schiffman M, Castle P, Rodriguz AC, Wacholder S,. Human Papillomavirus and cervical cancer. Lancet 2007; 370: 890 -905.
28. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M,. Human Papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008; 113 (7 Suppl): 1980 -1993.
29. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): A randomised controlled trial. Lancet Oncol 2009; 10: 672 -682.
30. Franco EL,. Is the UK ready to embrace HPV testing? Lancet Oncol 2009; 10: 643 -644.
31. Arbyn M, Ronco G, Meijer CJ, Naucler P,. Trials comparing cytology with Human Papillomavirus screening. Lancet Oncol 2009; 10: 935 -936.
32. Sasieni P, Castle PE, Cuzick J,. Further analysis of the ARTISTIC trial. Lancet Oncol 2009; 10: 841 -842; author reply 842-843.
33. Belinson J, Quao YL, Pretorius R, et al. Shanxi Province cervical cancer screening study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 439 -444.
34. Ferreccio C, Bratti MC, Sherman ME, Herrero R, Wacholder S, Hildesheim A, Burk RD, Hutchinson M, Alfaro M, Greenberg MD, Morales J, Rodriguez AC, Schussler J, Eklund C, Marshall G, Schiffman M,. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Ca Epid Biom Prev 2003; 12: 815 -823.
35. Zhao C, Florea A, Onisko A, Austin RM,. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: Results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol 2009; 114: 83 -89.
36. Wright TC, Jr., Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D,. Interim guidance for the use of Human Papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103: 304 -309.
37. Austin RM, Ramsy I,. Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations: A review of accumulated data. Acta Cytol 1998; 42: 178 -184.
38. Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, Bulten J, Arbyn M,. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: A randomized controlled trial. JAMA 2009; 302: 1757 -1764.
39. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M,. Accuracy of liquid based versus conventional cytology: Overall results of new technologies for cervical cancer screening: Randomised controlled trial. BMJ 2007; 335: 28.
40. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J,. Liquid compared with conventional cervical cytology: A systematic review and meta-analysis. Obstet Gynecol 2008; 111: 167 -177.
41. Davey E, Barratt A, Irwig L, Chan SF, Macaskill P, Mannes P, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid based versus conventional cervical cytology: A systematic review. Lancet 2006; 367: 122 -132.
42. Austin RM,. Computer-assisted Pap imaging: Another valuable tool in the challenge of Pap test screening for glandular neoplasia. Cancer Cytopathol 2010; 118: 65 -67.
43. Bernstein SJ, Sanchez-Ramos L, Ndubisi B,. Liquid based cervical cytologic smear study and conventional Papanicolaou smears: A meta-analysis of prospective studies comparing cytologic diagnosis and specimen adequacy. Am J Obstet Gynecol 2001; 185: 308 -317.
44. Ablufia O, Pezzullo JC, Shere DM,. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: A quantitative survey. Gynecol Oncol 2003; 90: 137 -144.
45. Hatch KD, Sheets E, Kennedy A, Ferris DG, Darragh T, Twiggs L,. Multicenter direct to vial evaluation of a liquid-based Pap test. J Lower Genital Tract Dis 2004; 8: 308 -312.
46. Smith HO, Benwick M, Qualls CF, Verschraegen CF, Wiggins C,. 30 year trends in cervical cancer incidence rates: A surveillance, epidemiology, and end results program population-based study. Abstract 196. Society of Gynecologic Oncologists' 2007 Meeting, March 4-7, 2007, San Diego, CA.
47. Davey E, d'Assuncao J, Irwig L, Macaskill P, Chan SF, Richards A, Farnsworth A,. Accuracy of reading liquid-based cytology slides using the ThinPrep Imager compared with conventional cytology: Prospective study. BMJ 2007; 335: 31 -35.
48. Cibas ES, Hong X, Crum CP, Feldman S,. Age-specific detection of high risk HPV DNAin cytologically normal, computer-imaged ThinPrep Pap samples. Gynecol Oncol 2007; 104: 702 -706.
49. Zhao C, Elishaev E, Yuan KH, Yu J, Austin RM,. Very low Human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests. Cancer 2007; 111: 292 -297.
50. Bansal M, Austin RM, Zhao C,. High risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid based Pap test samples from women 30 and older. Gynecol Oncol 2009; 115: 257 -261.
51. Austin RM, Onisko A, Druzdel M,. The Pittsburgh Cervical Cancer Screening Model: A risk assessment tool. Arch Pathol Lab Med 2010; 134: 744 -750.
52. Esserman L, Shieh Y, Thompson I,. Rethinking screening for breast cancer and prostate cancer. JAMA 2009; 302: 1685 -1692.
53. Sirovich BE, Woloshin S, Schwartz LM,. Screening for cervical cancer: Will women accept less? Am J Med 2005; 118: 151 -158.
54. Austin RM, Holladay EB,. Chapter X. Lessons from litigation in the Pap test by RM DeMay. ASCP Press: Chicago, Illinois; 2005.
55. Ko V, Tambouret RH, Kuebler DL, Black-Schaffer WS, Wilbur DC,. Human Papillomavirus testing using hybrid capture II with SurePath collection: Initial evaluation and longitudinal data provide clinical validation for this method. Cancer (Cancer Cytopathol) 2006; 108: 468 -474.
56. Stoler MH,. Human Papillomavirus biology and cervical neoplasia: Implications for diagnostic criteria and testing. Arch Pathol Lab Med 2003; 127: 935 -939.
57. Smith JS, Lindsay L, Brooke Hoots 1, Keys J, Franceschi S, Winer R, Clifford GM,. Human Papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121: 621 -632.
58. Andersson S, Rylander E, Larson B, Sugurdarottir S, Backlund I, Sallstrom J, Wylander E,. Types of Human Papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep 2003; 10: 175 -179.
59. Andersson SE, Rylander E, Larsson B, Strand A, Silfversvard E, Wilander E,. The role of Human Papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001; 37: 246 -250.
60. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV, Castle PE,. Human Papillomavirus genotype distributions: Implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475 -487.
61. Ge Y, Smith D, Schwartz MR, Mody DR,. Image-guided ThinPrep Papanicolaou tests and co-testing with high-risk Human Papillomavirus in women aged 30 years and older in a low-risk private practice population. Cancer Cytopathol 2009; 117: 326 -332.
62. Zhao C, Florea A, Austin RM,. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med 2010; 134: 103 -108.
63. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney WR,. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risk. Obstet Gynecol 2010; 115: 243 -248.
64. Cervical Cytology Screening, ACOG Practice Bulletin Number 109, Clinical Management Guidelines for Obstetrician-Gynecologists, December 2009.
65. Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: Evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100: 622 -629.
66. National, State, and Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years-United States, 2008. CDC Morbid Mortal Weekly Rep 2009; 58: 997 -1001.
67. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against Human Papillomavirus to prevent anogential diseases. NEJM 2007; 356: 1928 -1943. (Pubitemid 46740303)
68. FUTURE II Study Group. Quadrivalent vaccine against Human Papillomavirus to prevent high grade vervical lesions. NEJM 2007; 298: 743 -753.
69. Insinga RP, Liaw KL, Johnson LG, Madeleine MM,. A systematic review of the prevalence and attribution of Human Papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 1611 -1622.
70. Schiffman M,. Integration of Human Papillomavirus vaccination, cytology, and Human Papillomavirus testing. Cancer 2007; 111: 145 -153.
71. Kiviat NB, Hawes SE, Feng Q,. Screening for cervical cancer in the era of the HPV vaccine-The urgent need for both new screening guidelines and new biomarkers. JNCI 2008; 100: 308 -320.
72. Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D,. The impact of Human Papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 2009; 114: 360 -364.
73. Lynge E, Rebolj M,. Primary HPV screening for cervical cancer prevention: Results from European trials. Nat Rev Clin Oncol 2009; 6: 699 -706.
74. Rebolj M, Lynge E,. Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Sci 2010; 17: 1 -3.